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Introduction {#sec005}
============

Hepatitis C virus (HCV) infection is a serious global health threat with an estimated 150--170 million individuals chronically infected worldwide, resulting in 350,000 deaths each year due to associated cirrhosis and hepatocellular carcinoma (HCC) \[[@pone.0141715.ref001]--[@pone.0141715.ref003]\]. Mortality due to HCC has increased over the past four decades in many countries and in part is due to chronic HCV. \[[@pone.0141715.ref004], [@pone.0141715.ref005]\] Chronic HCV has also resulted in an enormous economic burden and lost productivity.\[[@pone.0141715.ref006]\] HCV infected individuals often remain asymptomatic for 30 years or more until liver disease is advanced \[[@pone.0141715.ref007]\]. Early detection therefore is critical as treatment usually leads to viral eradication, prevents progression of liver disease, and decreases all-cause mortality \[[@pone.0141715.ref008]\]. The recent development of safer, more tolerable and highly effective direct acting antiviral combinations offers the real possibility of cure for all HCV infected patients \[[@pone.0141715.ref008], [@pone.0141715.ref009]\]. This provides a clear and compelling rationale for identifying and screening groups at risk to avert the projected individual and economic burden from HCV.

The traditional approach to HCV control in most low prevalence countries is to screen groups with behavioral risk factors for exposure to infected blood, such as through intravenous drug use or receipt of blood products prior to routine screening. In spite of these programs, the majority of individuals with HCV (45--80%) in these countries remain undiagnosed and unaware of their infection until they develop chronic liver disease \[[@pone.0141715.ref010], [@pone.0141715.ref011]\]. To address this issue in the US, the Centre for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPTF) recently recommended a one-time HCV birth cohort screening program (Baby Boomers born between 1945 and 1965) in addition to risk factor based screening programs \[[@pone.0141715.ref010], [@pone.0141715.ref012]\].

Migrants born in intermediate and high HCV prevalence countries who live in low HCV prevalence countries are likely to be at increased risk for HCV due to exposure in their countries of origin \[[@pone.0141715.ref013]\]. Unlike low HCV prevalence countries where the primary mode of transmission is through intravenous drug use, most infections in intermediate and high HCV endemic countries are acquired iatrogenically through contaminated needles, medical procedures or receipt of unscreened contaminated blood products \[[@pone.0141715.ref007], [@pone.0141715.ref014]\]. Most migrants are therefore unlikely to be detected in current HCV screening programs. Furthermore they have not been identified as a group that should be targeted for HCV screening with the exception of recent UK and Canadian guidelines.\[[@pone.0141715.ref013], [@pone.0141715.ref015]\] This is primarily due to the fact that the HCV burden in this population has not been adequately quantified.

To address this knowledge gap, we carried out a systematic review and meta-analysis on the seroprevalence of HCV in migrants living in several different low HCV prevalence, high migrant-receiving host countries.

Materials and Methods {#sec006}
=====================

Data sources and searches {#sec007}
-------------------------

This article was prepared and reported according to PRISMA guidelines ([S1 Appendix](#pone.0141715.s001){ref-type="supplementary-material"}) \[[@pone.0141715.ref016]\]. Four electronic databases, including Medline, Medline In-Process, EMBASE, and the Cochrane Database of Systematic Reviews were searched from inception until June 17, 2014. The search strategy was developed by a medical librarian and the strategy and search terms for MEDLINE are listed in supporting information ([S2 Appendix](#pone.0141715.s002){ref-type="supplementary-material"}). In summary, search terms included those for hepatitis C and the population of interest (migrants, foreign born, immigrants, refugees, asylum seekers) using a combination of text words and subject headings appropriate to each database. No limits by date or language were applied to the search. Additional studies were identified by examining the bibliographies of eligible studies and review articles.

Study selection and quality assessment {#sec008}
--------------------------------------

Original studies that reported data on the anti-HCV prevalence in migrants originating from low/intermediate income, intermediate/high HCV prevalence countries, and arriving in high income, low/intermediate HCV prevalence countries, were included. Conference abstracts and proceedings were not included due to concerns regarding the inability to determine the quality of the methods. We adapted the GRADE method to assess the quality of the body of evidence and assessed the risk of bias, inconsistency, indirectness, and imprecision of the data \[[@pone.0141715.ref017], [@pone.0141715.ref018]\] ([S3 Appendix](#pone.0141715.s003){ref-type="supplementary-material"}). We did not assess small study effects (e.g. publication bias) as this is not reliable for seroprevalence studies \[[@pone.0141715.ref019]\].

We only included studies judged to have a low to moderate risk of selection or detection bias. Studies were included if the entire population or a random sample of individuals captured in a particular settings such as clinics conducting immigrant and refugee screening, general primary care or medical clinics, and prenatal clinics over a set period of time and all participants were offered HCV blood testing. Studies were excluded if; 1) If a non-random sample of individuals from a site were recruited or if only selected individuals had HCV serologic testing performed, 2) surveys in which \<65% of eligible persons agreed to participate in the study, and 3) the study population focused on migrants populations judged to be at either at lower risk (for example healthy blood donors \[[@pone.0141715.ref020]--[@pone.0141715.ref022]\]) or increased risk for HCV due to specific lifestyles or environmental conditions (i.e. sex workers, intravenous drug use, incarcerated migrants, men having sex with men (MSM), individuals being treated for chronic liver disease).

Data extraction {#sec009}
---------------

Two authors screened the titles and abstracts of all identified articles, reviewed and selected full-text articles, and independently extracted and entered data from each included study into a database. Data on study design, recruitment method, serologic screening test used, confirmatory test used, study duration, country of landing, mean or median age, gender, migrants' region of origin, and migration status were extracted.

The primary study outcome was the proportion of subjects with the presence of HCV antibody (anti-HCV) detected by an enzyme immunoassay (EIA) with or without reported confirmatory testing (previous and current infection). Categories of HCV antibody seroprevalence for individual countries were defined as: very low (\<1%), low (1- \<2%), intermediate (2-\<3%), high (3-\<5%), and very high (≥ 5%). Age was defined as the mean or median age of the study population categorized into the following groups: ≤18 years, 19--29 years, and ≥ 30 years. Studies on children were classified as those where all study subjects were ≤ 18 years of age. Region of origin and income level were defined according to the World Bank classifications \[[@pone.0141715.ref023]\]. Regions of origin were categorized as: Latin America and the Caribbean, Eastern Europe and Central Asia, Middle East and North Africa, Sub-Saharan Africa, South Asia, and East Asia and the Pacific Categories for 'Combined Africa' and 'Combined Asia' were added to the region of origin variable, so that studies that only classified migrants as originating from Africa or Asia could be included. Studies with participants from several regions of origin were described as "Mixed", however anti-HCV prevalence by region of origin was estimated if the data were reported this manner. Migration status was classified as; 'immigrants' (immigrants and adopted children), 'refugees' (refugees and asylum seekers), and 'other' (mixed populations or migrant status not mentioned).

Data synthesis and analysis {#sec010}
---------------------------

For each study, the prevalence of HCV antibodies (includes previous and current infection) and viremic HCV infections were calculated as the reported numbers of subjects positive for anti-HCV or HCV PCR, respectively, divided by the total number of subjects screened for each of these markers. Proportions were transformed with the logit transformation and pooled using a random-effects model \[[@pone.0141715.ref024], [@pone.0141715.ref025]\]. The logit transformation was used to avoid studies with few events from being weighed too heavily in the random-effects model and the multivariate analysis, which used a random-effects logistic regression model, is also based on the logit transformation \[[@pone.0141715.ref026]\]. The logit transformation, arcsine and Freeman-Turkey methods, different methods used in meta-analysis of proportions were compared in a sensitivity analysis. Overall heterogeneity among studies was assessed using the *I* ^2^ statistic and estimates were stratified by age group, region of origin and migration status, as these variables were believed *a priori* to be important predictors of chronic HCV infection \[[@pone.0141715.ref027]\]. The meta-analysis was performed using the *metaprop* command of the meta package (3.6--0) in R (version 3.1.3) \[[@pone.0141715.ref028]\]. A random-effects meta-regression, using the *glmer* command of the lme4 package (version 1.0--4) to fit generalized linear mixed-models in R, was used to further explore heterogeneity. Unadjusted models for each of age group (reference: ≤ 18 years), migrant status (reference: immigrants), and region of origin (reference: Latin America & Caribbean) with anti-HCV prevalence as the outcome were run (see [Table 1](#pone.0141715.t001){ref-type="table"} for description of each categorical variable). Two adjusted meta-regression models were run and included; 1) age and migrant status, and 2) migrant status and region of origin. It was not possible to create a model to adjust for age by region of origin because the age of migrants was not stratified by region of origin in the included studies \[[@pone.0141715.ref029]\]. We created maps of country specific anti-HCV prevalence with data from the WHO \[[@pone.0141715.ref030]\] or more recent estimates \[[@pone.0141715.ref031]--[@pone.0141715.ref035]\] using the ArcGIS-9 software (ESRI data and Maps 9·3, 2008; USA). Weighted regional HCV seroprevalence (categorized by World Bank classification) were calculated from these same country specific seroprevalence data and multiplied by the 2009 country specific population estimates from the World Bank (Tables A and B in [S4 Appendix](#pone.0141715.s004){ref-type="supplementary-material"}) \[[@pone.0141715.ref023]\]. Regional seroprevalence estimates from our meta-analysis were superimposed on the same map for comparison.

10.1371/journal.pone.0141715.t001

###### Characteristics of included studies \[[@pone.0141715.ref070]--[@pone.0141715.ref119]\].

Abbreviations: EIA, enzyme immunoassay; CIA, chemiluminescent immunoassay; PCR, polymerase chain reaction.

![](pone.0141715.t001){#pone.0141715.t001g}

                                                                Number of studies (%)                     Sample size (%)
  ------------------------------------------------------------- ----------------------------------------- -----------------
  **Total**                                                     50 (100)                                  38 635 (100)
  **Age group** [^a^](#t001fn001){ref-type="table-fn"}                                                    
  Reported                                                      **35 (70.0)**                             19 309 (50.0)
  ≤ 18 years                                                    11 (31.4)                                 3767 (19.5)
  19--29 years                                                  15 (42.9)                                 9172 (47.5)
  ≥ 30 years                                                    9 (25.7)                                  6370 (33.0)
  Not reported                                                  15 (30.0)                                 19 326 (50.0)
  **Population Characteristics**                                                                          
  Children[^b^](#t001fn002){ref-type="table-fn"}                9 (18.0)                                  2452 (6.3)
  Pregnant Women                                                8 (16.0)                                  8347 (21.6)
  General Population                                            33 (66.0)                                 27 838 (72.1)
  **Migration status**                                                                                    
  ***Immigrant***                                               29 (58.0)                                 17 800 (46.1)
  Immigrant                                                     21 (42.0)                                 16 275 (42.1)
  Adopted child                                                 7 (14.0)                                  1350 (3.4)
  Foreign student                                               1 (2.0)                                   175 (0.5)
  ***Refugee***                                                 11 (22.0)                                 5186(12.3)
  Refugee                                                       10 (20.0)                                 4915 (13.4)
  Asylum seeker                                                 1 (2.0)                                   271 (0.7)
  ***Other***                                                   10 (20)                                   15649 (40.5)
  Mixed immigrant and refugee population                        6 (12.0)                                  11 350 (29.4)
  Not specified                                                 4 (8.0)                                   4299 (11.1)
  **Region of origin** [^c^](#t001fn003){ref-type="table-fn"}                                             
  Latin America and Caribbean                                   13 (12.5)                                 5240 (13.6)
  Eastern Europe and Central Asia                               25 (24.0)                                 7505 (19.4)
  Middle East and North Africa                                  11 (10.6)                                 2681 (6.9)
  Sub-Saharan Africa                                            15 (14.4)                                 4446 (11.5)
  South Asia                                                    4 (3.8)                                   354 (0.9)
  East Asia and Pacific                                         7 (6.7)                                   1007 (2.6)
  Combined Africa                                               9 (8.7)                                   2095 (5.4)
  Combined Asia                                                 10 (9.6)                                  1107 (2.9)
  Mixed                                                         10 (9.6)                                  14 200 (36.8)
  Total[^d^](#t001fn004){ref-type="table-fn"}                   104 (100)                                 38 635 (100)
  **Country of landing**                                                                                  
  Australia                                                     3 (6.0)                                   7939 (20.5)
  Canada                                                        2 (4.0)                                   339 (0.9)
  France                                                        3 (6.0)                                   1911 (4.9)
  Germany                                                       1 (2.0)                                   1025 (2.7)
  Greece                                                        6 (12.0)                                  5146 (13.3)
  Israel                                                        3 (6.0)                                   1480 (3.8)
  Italy                                                         11 (22.0)                                 5011 (13.0)
  Netherlands                                                   2 (4.0)                                   1239 (3.2)
  Spain                                                         15 (30.0)                                 11 915 (30.8)
  Sweden                                                        1 (2.0)                                   88 (0.2)
  United States                                                 3 (6.0)                                   2542 (6.6)
  **Study Setting for Screening**                                                                         
  Adopted Children                                              7 (14.0)                                  1350 (3.5)
  Migrant screening[^e^](#t001fn005){ref-type="table-fn"}       15 (30.0)                                 14 060 (36.4)
  Prenatal screening                                            9 (18.0)                                  9328 (24.1)
  General clinics                                               12 (24.0)                                 6832 (17.7)
  Tropical medicine                                             4 (8.0)                                   3827 (9.9)
  Surveys                                                       3 (6.0)                                   3238 (8.4)
  **Decade of study publication**                                                                         
  1990--1999                                                    14 (28.0)                                 7655 (19·8)
  2000--2009                                                    27 (54.0)                                 22518 (58·2)
  2010--2013                                                    9 (18.0)                                  8462 (22·0)
  **Diagnostic method**                                                                                   
  EIA/CIA alone                                                 28 (56.0)                                 20820 (53.9)
  EIA/CIA + confirmatory method                                 22 (44.0)                                 17814 (46.1)
  **EIA generation**                                                                                      
  1^st^ generation                                              1 (2.0)                                   88 (0.2)
  2^nd^ generation                                              12 (24.0)                                 6632 (17.2)
  3^rd^ generation                                              37 (74.0)                                 31915 (82.6)
  **PCR**                                                       6[^f^](#t001fn006){ref-type="table-fn"}   5139 (13.3)

^a^ Age group based on mean or median age. Only 35 of the 50 studies included data on age. The remaining studies reported no information on age specific to the migrant participants or included a range that overlapped more than one age group.

^b^ Studies where all migrants were ≤ 18 years were considered to be studies of children.

^c^ According to World Bank classification

^d^ The number of studies exceeds the 50 studies included in this review and meta-analysis because a single study could report seroprevalence in multiple regions of origin.

^e^ Migrants detained upon arrival by boat.

^f^ Of the nine studies (N = 5932), only six performed PCR on all anti-HCV positive participants (N = 5139)

Results {#sec011}
=======

A total of 973 titles and abstracts were screened, 173 full text articles were reviewed, and 50 were included in this study ([Fig 1](#pone.0141715.g001){ref-type="fig"}). Included studies reported on 38 635 participants from all world regions who arrived in Australia, Canada, Europe, Israel and the United States ([Table 1](#pone.0141715.t001){ref-type="table"}). Across all studies, there was a low to moderate risk of bias, moderate to high inconsistency, moderate imprecision, and low indirectness. We therefore considered the overall quality of the body of data to be low to moderate ([S3 Appendix](#pone.0141715.s003){ref-type="supplementary-material"}). Although all studies measured HCV antibodies, only 44% (N = 22) of studies reported confirmatory testing. The prevalence of antibodies, was similar in those studies in which a confirmatory test was reported or not \[2.1% (95% CI, 1.2--3.6) vs. 1.8% (95% CI, 1.1--2.8%), respectively\] (data not shown).

![Flowchart of the identification, screening, and inclusion/exclusion of studies.](pone.0141715.g001){#pone.0141715.g001}

All studies were therefore included in the meta-analysis, and resulted in an overall anti-HCV prevalence of 1.9% (95% CI, 1.3--2.7) ([Table 2](#pone.0141715.t002){ref-type="table"}). A sensitivity analysis was performed and compared the overall anti-HCV prevalence estimates using the logit transformation, arcsine and Freeman-Turkey and all yielded similar results \[1.91 (95% CI, 1.35--2.69), 2.2 (95% CI, 1.4--3.1) and 2.1 (95% CI, 1.4--3.0) respectively\] \[[@pone.0141715.ref026]\]. Only six studies (N = 5139 individuals) reported results of HCV PCR testing. In these studies, 75% of individuals were found to have viremic infection (i.e. HCV RNA was detected). Significant heterogeneity was found in the overall pooled HCV seroprevalence estimate (I^2^, 96.1% \[95% CI, 95.5--96.7\]) that decreased but was still at least moderate when data were stratified by age and region of origin, known important predictors of HCV seroprevalence ([Table 2](#pone.0141715.t002){ref-type="table"}).

10.1371/journal.pone.0141715.t002

###### Pooled HCV seroprevalence overall and stratified by migration status, region of origin, and age.

Abbreviations: CI, confidence interval.

![](pone.0141715.t002){#pone.0141715.t002g}

                                                   N studies   N subjects   Seroprevalence % (95% CI)   I^2^% (95% CI)
  ------------------------------------------------ ----------- ------------ --------------------------- -------------------
  **Overall**                                      50          38 635       1.9 (1.4, 2.7)              96.1 (95.5, 96.7)
  **Overall (without children)**                   41          36 183       2.2 (1.6, 3.2)              96.7 (96.1, 97.2)
  **Age** [^a^](#t002fn001){ref-type="table-fn"}                                                        
  ≤ 18 years                                       11          3767         0.8 (0.4, 1.6)              63.8 (30.8, 81.1)
  19--29 years                                     15          9172         2.0 (1.3, 3.1)              88.5 (82.7, 92.4)
  ≥ 30 years                                       9           6370         5.6 (3.7, 8.5)              93.6 (89.9, 95.9)
  **Population category**                                                                               
  Children[^b^](#t002fn002){ref-type="table-fn"}   9           2452         0.6 (0.3, 1.3)              16.1 (0, 58.2)
  Pregnant Women                                   8           8347         2.0 (1.3, 3.1)              85.5 (73.3, 92.1)
  General Population                               33          27838        2.3 (1.6, 3.5)              96.8 (96.2, 97.3)
  **Migrant status**                                                                                    
  Immigrants                                       29          17 800       2.3 (1.5, 3.5)              95.9 (94.9, 96.7)
  Refugees                                         11          5186         1.3 (0.8, 2.2)              69.4 (42.9, 83.6)
  Other[^c^](#t002fn003){ref-type="table-fn"}      10          15 649       2.2 (1.2, 3.9)              95.8 (93.9, 97.1)
  **Region of origin**                                                                                  
  Latin America & Caribbean                        13          5240         0.7 (0.5, 1.1)              19.6 (0, 57.6)
  Eastern Europe & Central Asia                    25          7505         2.2 (1.3, 3.8)              89.3 (85.5, 92.1)
  Middle East & North Africa                       11          2681         1.4 (0.8, 2.4)              38.3 (0, 69.6)
  Sub-Saharan Africa                               15          4446         4.4 (2.6, 7.4)              91.5 (87.7, 94.2)
  South Asia                                       4           354          4.8 (0.9, 21.3)             69.7 (12.7, 89.5)
  East Asia & Pacific                              7           1007         1.6 (0.9, 2.7)              0 (0, 53.5)
  Combined Africa                                  9           2095         4.6 (2.7, 7.7)              79.2 (61.1, 88.9)
  Combined Asia                                    10          1107         3.8 (2.3, 6.3)              39.4 (0, 71.1)
  **Setting for screening**                                                                             
  Adopted kids                                     7           1350         0.7 (0.4, 1.5)              0 (0, 0.6)
  Migrant screening                                15          14 060       1.3 (0.9, 2.0)              80.5 (68.7, 87.8)
  General clinics                                  28          23 225       2.9 (1.9, 4.2)              96.7 (96.0, 97.3)
  **Decade of publication**                                                                             
  1990--1999                                       14          7655         2.8 (1.6, 4.7)              93.2 (90.3, 95.3)
  2000--2009                                       27          22518        1.6 (1.0, 2.3)              90.9 (88.0, 93.1)
  2010--2013                                       9           8462         2.4 (1.3, 4.6)              96.8 (95.4, 97.8)
  **EIA test generation**                                                                               
  1^st^ generation                                 1           88           2.3 (0.6, 8.6)              \-
  2^nd^ generation                                 12          6632         2.2 (1.4, 3.5)              86.9 (78.9, 91.8)
  3^rd^ generation                                 37          31915        1.8 (1.2, 2.8)              96.8 (96.2, 97.3)

^a^ Only 35 of the 50 studies provided information regarding age of the study population and age groups were classified by mean or median age of the study population.

^b^ Population Category included all studies: Children (all subjects were \<18 years), pregnant women, general population (mixed ages including some children).

^c^ The 'Other' subgroup includes studies where results were not stratified by migrant status.

Age was a significant predictor of HCV seroprevalence in the 35 of 50 studies that reported the age of the studied population ([Table 2](#pone.0141715.t002){ref-type="table"}, [S1 Fig](#pone.0141715.s005){ref-type="supplementary-material"}). Individuals in the ≥ 30 age group were more likely to have HCV antibodies as compared to those ≤18 years of age \[5.6% (95% CI, 3.7--8.5% vs. 0.8% (95% CI, 0.4--1.6)\] and an adjusted meta-regression model found a 8.6 (95% CI, 3.0--24.7) increased odds of being HCV positive after adjusting for migration status ([Table 2](#pone.0141715.t002){ref-type="table"}). In addition, the anti-HCV prevalence in studies that only included children was significantly lower than the seroprevalence in the general population \[0.6% (95% CI, 0.3--1.3) vs. 2.3% (95% CI, 1.6--3.5)\] ([Table 2](#pone.0141715.t002){ref-type="table"}, [Fig 2](#pone.0141715.g002){ref-type="fig"}). When studies that only included children were removed from the analysis, the overall anti-HCV prevalence increased from 1.9% (95% CI, 1.4--2.7) to 2.2% (95% CI, 1.6--3.2). Anti-HCV prevalence also varied significantly by region of origin, and was high (\>3%) in migrants from South Asia, Sub-Saharan Africa, combined Africa and combined Asia, intermediate (2--3%) in migrants from Eastern Europe, and low (\< 2%) in migrants from the Middle East & North Africa, East Asia & the Pacific, and Latin America and the Caribbean ([Table 2](#pone.0141715.t002){ref-type="table"}, [Fig 3](#pone.0141715.g003){ref-type="fig"}). Significant differences in the seroprevalence between regions of origin remained in the meta-regression model even after adjusting for migration status (data not shown). The regional HCV seroprevalence estimates for migrants from our meta-analysis were similar or slightly lower than the corresponding HCV seroprevalence estimates from the WHO in the general population in their regions of origin with the exception of Sub-Saharan Africa and South Asia ([Table 2](#pone.0141715.t002){ref-type="table"}, [Fig 4](#pone.0141715.g004){ref-type="fig"}). Calendar time did not affect our results as anti-HCV prevalence was similar across all decades and heterogeneity within groups remained high.

![HCV seroprevalence for all included studies stratified by population group and sorted by year of publication (Forest Plot).\
Regions of Origin: Latin America & Caribbean (LAC), Eastern Europe & Central Asia (ECA), Middle East & North Africa (MENA), Sub-Saharan Africa (SSA), South Asia (SA), East Asia & Pacific (EAP), Mixed (a single study reporting seroprevalence from multiple regions of origin).](pone.0141715.g002){#pone.0141715.g002}

![HCV seroprevalence for all included studies stratified by migrants region of origin (Forest Plot).](pone.0141715.g003){#pone.0141715.g003}

![Anti-HCV seroprevalence stratified by region of origin (Map).\
Weighted regional HCV estimates (in bold) were based on country specific seroprevalence from the WHO or other more recent data (Table A in [S4 Appendix](#pone.0141715.s004){ref-type="supplementary-material"}) and 2009 country population estimates from the World Bank. ^a^ Seroprevalence excluding Egypt. \* Estimates from our random-effects meta-analysis.](pone.0141715.g004){#pone.0141715.g004}

Discussion {#sec012}
==========

The findings of this study suggest that migrants from intermediate or high HCV prevalence countries represent an important risk group for HCV infection. The overall pooled anti-HCV seroprevalence in migrants in this study was 1.9% (1.4%-2.7%). Those from Sub-Saharan Africa, Asia and Eastern Europe and older age groups had the highest risk with anti-HCV prevalence ranging from 2.2% to 5.6%.

The regional HCV seroprevalence estimates from our study were a little lower or higher but fell within a similar range and pattern when compared to published studies from migrant source countries \[[@pone.0141715.ref001]--[@pone.0141715.ref003], [@pone.0141715.ref032]--[@pone.0141715.ref035]\]. Globally, anti-HCV prevalence is highest in Asia, Africa, Eastern Europe, and North Africa & the Middle East, ranging from 2--4%, whereas in North America, Latin American & the Caribbean, most Western European countries and Australia, the anti-HCV prevalence is less than 1.5% \[[@pone.0141715.ref003], [@pone.0141715.ref030]--[@pone.0141715.ref035]\]. We also found that anti-HCV seroprevalence increased with age and was higher in adults as compared to children. The similar age trend and the pattern and rank of regional estimates provide external validity to our results.

Despite similarities to published regional anti-HCV seroprevalence, the heterogeneity of the overall pooled estimate from our study was high and remained moderate even after stratification by important HCV predictive variables such as age and region of origin. The high overall and residual heterogeneity after stratification may reflect; 1) the true variability of HCV epidemiology within countries and regions, 2) characteristics of migrants included in our study and/or 3) the inability to adequately adjust for age and country of origin due the fact that data were not stratified by both variables in the studies included.

HCV epidemiology is highly variable both within and between countries and regions of origin. HCV is unevenly distributed in most countries and is usually concentrated in certain risk groups or birth cohorts and may change over time as affected cohorts grow older. The prevalence of HCV in any given country is determined by the calendar time the virus was introduced into the country, when or if blood screening is performed, and the ongoing risk of HCV exposure \[[@pone.0141715.ref002], [@pone.0141715.ref036]\]. Age is also an important predictor of HCV infection and increases with age in most settings \[[@pone.0141715.ref002]\]. Regional HCV prevalence may be heterogeneous due to the wide range of anti-HCV prevalence of individual countries within the same region \[[@pone.0141715.ref034], [@pone.0141715.ref035], [@pone.0141715.ref037]\]. The most striking example is the Middle East & North Africa which contains both Egypt with very high anti-HCV prevalence (\>14%) and Djibouti, which has a low prevalence (\<1%). Our regional estimates may therefore have been influenced by the number of migrants from high burden countries such as Egypt in the North African region or Pakistan in the South Asian region. We could neither adjust for this nor estimate how much this may have affected the study results. Calendar time did not affect our results as anti-HCV prevalence was similar across all decades and heterogeneity within groups remained high.

The regional anti-HCV estimates in our study were slightly lower or higher than those reported in source countries. This may be due to the fact that the migrants included in our review may have differed from the populations in their countries of origin in several ways. First, the risk profile of the two populations may be different. The majority of country level HCV estimates are based on data extrapolated from or modeled from data obtained from adult groups that are either at low or high HCV risk, whereas these populations were excluded in our study \[[@pone.0141715.ref010], [@pone.0141715.ref031]--[@pone.0141715.ref035], [@pone.0141715.ref037], [@pone.0141715.ref038]\]. Second, the inclusion of children in our study may have decreased our overall rate compared to reported rates. When children were excluded from our sample, the overall prevalence increased from 1.9% to 2.2%, an estimate closer to global estimates \[[@pone.0141715.ref001]--[@pone.0141715.ref003]\]. Finally, migrants may have truly lower HCV rates compared to those living in source countries due to the "healthy immigrant" effect. Many migrants, excluding refugees, are self-selected and have a higher socio-economic status (SES) and higher levels of education as compared to those living in their countries of origin \[[@pone.0141715.ref039]\].

The data included in this review has a number of limitations. Age was missing in 50% of study subjects and data in each region of origin was not stratified by age. We were therefore unable to adjust for both age and region of origin in the meta-regression and this may explain some of the residual heterogeneity despite stratification by these variables. There were very few study subjects from certain geographic regions such as South Asia leading to low precision in this group. Measurement bias is possible but unlikely had a large impact on the accuracy of our results. This is because the majority of studies (82.6%) used a third generation EIA and prevalence estimates were similar for studies with and without confirmatory testing. Sources of grey literature were not systematically searched and thus some data may have been missed. Finally, given the small number of studies (N = 6 accounting for only 13% of the study population) reporting HCV PCR we were not able to estimate the number of viremic HCV cases in migrants that could benefit from antiviral therapy. Despite these limitations and the uncertainty regarding all the source of the heterogeneity of our study results, it is both plausible and likely that immigrants from intermediate and high HCV endemic countries have an HCV prevalence that is similar or slightly lower than that in their source countries. The strength of this study is that it included a large number of migrants over four decades arriving in all major immigrant receiving regions.

Untreated HCV is an enormous health and economic burden that is projected to increase over the next decade unless asymptomatic infected individuals are detected and treated prior to developing end stage liver disease \[[@pone.0141715.ref006]\]. Eradication of HCV is now within reach given the recent availability of highly effective, well tolerated, short course, direct acting anti-viral treatments \[[@pone.0141715.ref009], [@pone.0141715.ref040]\]. Identifying and treating all individuals with HCV infection therefore, is more important than ever in order to decrease the rising economic and individual burden from HCV.

The majority of migrants (\>70%) received in Canada and most European countries originate from intermediate and high HCV prevalence countries \[[@pone.0141715.ref041]--[@pone.0141715.ref062]\]. Recent studies show that European migrants make up a disproportionate number of HCV cases and have a higher prevalence of HCV compared to host populations \[[@pone.0141715.ref032], [@pone.0141715.ref037]\]. Similarly in Canada, migrants were estimated to accounted for 20% of HCV cases in 2002 \[[@pone.0141715.ref063]\]. Migrants generally lack traditional HCV risk behaviors given that they are most likely to have been infected in their countries of origin through contaminated needles, procedures and blood products \[[@pone.0141715.ref064]\]. Neither the risk factor based program, which detects \<50% of HCV cases or the new CDC birth cohort screening program will detect HCV in most migrants \[[@pone.0141715.ref010]\]. Despite the well-known differences in global distribution of HCV and the potential increased risk of HCV in many migrants, only the UK has recently recommended HCV screening in migrants who were born in countries with intermediate or high seroprevalence of HCV antibodies (2% or greater).

Adult migrants originating from intermediate and high HCV prevalence regions such as Africa, Asia and Eastern Europe are an ideal additional group to consider for targeted HCV screening. Given the limitations of our study, screening would serve, at least, to provide robust seroprevalence and viremic data at the country level to identify which migrants have the highest HCV infection rates. Several studies have shown that it is cost effective to screen the general population at an anti-HCV prevalence of 3% with older interferon based therapies \[[@pone.0141715.ref065], [@pone.0141715.ref066]\]. The cost-effectiveness of screening and treatment with new highly effective but costly medications is still to be determined \[[@pone.0141715.ref067], [@pone.0141715.ref068]\]. Cost-effectiveness analysis of HCV screening in migrants would help guide the decision as to which migrants would benefit the most from screening for HCV.

The recent revolution in HCV treatment provides promise to cure all infected patients. Recent studies have shown that HCV can be eliminated in the next 15--20 years with focused strategies to screen and cure current infection as well as prevent new infections \[[@pone.0141715.ref040], [@pone.0141715.ref069]\]. Additional groups at increased HCV risk will need to be identified and treated if this potential is to be realized. In the current HCV context, the results of our study suggest that adult migrants originating from intermediate or high endemic countries are at high risk for HCV and may benefit from targeted HCV screening.
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